期刊
ACTA PAEDIATRICA
卷 110, 期 4, 页码 1299-1306出版社
WILEY
DOI: 10.1111/apa.15641
关键词
acute lower respiratory infections; Down syndrome; Japan; palivizumab; respiratory syncytial virus
类别
资金
- AbbVie Inc [10286]
The study revealed an increase in the percentage of children with Down syndrome in Japan receiving Palivizumab, and a significant decrease in the RSV-associated hospitalization rate for children born between 2013-2015 without congenital heart disease and born at a gestational age >= 36 weeks.
Aim Down syndrome has been considered an independent risk factor for respiratory syncytial virus (RSV) infection. Palivizumab, an anti-RSV humanised monoclonal antibody, was currently approved for all children with Down syndrome in Japan. To investigate the change in RSV-associated hospitalisation (RSVH) rates before and after the universal approval of palivizumab in Japan in 2013, we conducted a nationwide retrospective survey. Methods We conducted a nationwide, retrospective, questionnaire survey across paediatric institutions in Japan. The recruited children with Down syndrome were divided into two groups: those born April 2010 to March 2013 (2010-2012 cohort) and those born April 2013 to March 2016 (2013-2015 cohort). Results Of the 664 institutions, 321 (48.3%) replied, and a total of 3929 children with Down syndrome were registered. The percentage of children who received palivizumab increased from 49.2% to 82.2%. The cumulative RSVH rate showed a decreased trend in the 2013-2015 cohort (OR, 0.83; 95%CI, 0.63-1.10), while the rate of these children (without CHD and born at a gestational age >= 36 weeks) was significantly decreased in the 2013-2015 cohort (OR, 0.56; 95%CI, 0.34-0.92). Conclusion The cumulative RSVH rate tended to be decreased after approval for all children with Down syndrome although the result was not significant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据